Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition

[1]  D. Kohda,et al.  The benzylisoquinoline alkaloids, berberine and coptisine, act against camptothecin-resistant topoisomerase I mutants , 2021, Scientific Reports.

[2]  T. Ishizaki,et al.  Analysis of Chromosomal DNA Fragmentation in Apoptosis by Pulsed-Field Gel Electrophoresis. , 2020, Methods in molecular biology.

[3]  K. Hanada.  Introduction and Perspectives of DNA Electrophoresis. , 2020, Methods in molecular biology.

[4]  Y. Pommier,et al.  Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. , 2018, Journal of medicinal chemistry.

[5]  A. Roy,et al.  Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. , 2018, Cancer genomics & proteomics.

[6]  Fengzhi Li,et al.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? , 2017, American journal of cancer research.

[7]  G. Chillemi,et al.  Type I DNA Topoisomerases. , 2017, Journal of medicinal chemistry.

[8]  Y. Yamaoka,et al.  Detection of DNA double‐strand breaks by pulsed‐field gel electrophoresis , 2017, Genes to cells : devoted to molecular & cellular mechanisms.

[9]  Chun Wu,et al.  Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone , 2016, J. Chem. Inf. Model..

[10]  Reham Atteya,et al.  Topoisomerase-mediated chromosomal break repair: an emerging player in many games , 2015, Nature Reviews Cancer.

[11]  Chunaram Choudhary,et al.  FBH1 influences DNA replication fork stability and homologous recombination through ubiquitylation of RAD51 , 2015, Nature Communications.

[12]  A. Desideri,et al.  Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico , 2013, Molecular Cancer.

[13]  Tingjun Hou,et al.  Molecular Principle of Topotecan Resistance by Topoisomerase I Mutations through Molecular Modeling Approaches , 2013, J. Chem. Inf. Model..

[14]  I. Hickson,et al.  FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress , 2013, Nature Communications.

[15]  Marcus D. Hanwell,et al.  Avogadro: an advanced semantic chemical editor, visualization, and analysis platform , 2012, Journal of Cheminformatics.

[16]  S. Keir,et al.  Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[17]  Y. Pommier,et al.  Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I–DNA complexes , 2011, The Journal of cell biology.

[18]  Y. Pommier,et al.  Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282 , 2011, Molecular Cancer Therapeutics.

[19]  B. Teicher,et al.  Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment , 2011, Clinical Cancer Research.

[20]  A. Causse,et al.  New Topoisomerase I mutations are associated with resistance to camptothecin , 2011, Molecular Cancer.

[21]  M. Takagi,et al.  Transcription-dependent Activation of Ataxia Telangiectasia Mutated Prevents DNA-dependent Protein Kinase-mediated Cell Death in Response to Topoisomerase I Poison* , 2010, The Journal of Biological Chemistry.

[22]  T. Helleday,et al.  Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair , 2010, Molecular cell.

[23]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[24]  Y. Pommier.  DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition , 2009 .

[25]  Y. Pommier.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. , 2009, Chemical reviews.

[26]  Y. Pommier,et al.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives , 2009, Molecular Cancer Therapeutics.

[27]  M. Bjornsti,et al.  Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin* , 2008, Journal of Biological Chemistry.

[28]  R. Kanaar,et al.  The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks , 2007, Nature Structural &Molecular Biology.

[29]  Daniel A. Koster,et al.  Antitumour drugs impede DNA uncoiling by topoisomerase I , 2007, Nature.

[30]  Katsuhiro Hanada,et al.  The structure‐specific endonuclease Mus81–Eme1 promotes conversion of interstrand DNA crosslinks into double‐strands breaks , 2006, The EMBO journal.

[31]  S. Bekker-Jensen,et al.  Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1 , 2005, The Journal of cell biology.

[32]  Giovanni Chillemi,et al.  Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I* , 2003, Journal of Biological Chemistry.

[33]  Junjie Chen,et al.  Accumulation of Checkpoint Protein 53BP1 at DNA Breaks Involves Its Binding to Phosphorylated Histone H2AX* , 2003, Journal of Biological Chemistry.

[34]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Jang-Yang Chang,et al.  Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. , 2002, Cancer research.

[36]  Masahiro Fukuoka,et al.  Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. , 2002, Lung cancer.

[37]  Y. Pommier,et al.  Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. , 2002, Biochemistry.

[38]  G. Dianov,et al.  A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro. , 2001, Nucleic acids research.

[39]  Y. Pommier,et al.  Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. , 2001, Cancer research.

[40]  Y. Pommier,et al.  Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. , 2001, Cancer research.

[41]  Y. Pommier,et al.  Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. , 2000, Cancer research.

[42]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[43]  E. Rubin,et al.  The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. , 1999, Biochemistry.

[44]  A. Kuin,et al.  Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. , 1997, Cancer research.

[45]  Y. Pommier,et al.  Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases , 1997, Leukemia.

[46]  A. Fojo,et al.  Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. , 1997, Cancer research.

[47]  B. Gatto,et al.  Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. , 1996, Cancer research.

[48]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[49]  H. Strutt,et al.  Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. , 1991, Nucleic acids research.